KASINGER JAMES R. sold $51K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 1,040 shares of CRISPR Therapeutics AG (CRSP) at $49.26 on 2026-10-14.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Oct 15, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

This provides incremental sentiment information but does not indicate a new business development, regulatory action, or financial guidance change.

02

Market read

Traders may note the insider sale, but the disclosed transaction size is unlikely to drive material repricing absent other catalysts.

03

What to watch

Insider sales are common and often not predictive; without accompanying operational or guidance changes, the trading signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-10-15, transaction dated 2026-10-14

Background

The article is an SEC Form 4 insider transaction disclosure for CRISPR Therapeutics AG.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

CRSP Form 4 shows General Counsel James R. Kasinger sold 1,040 shares in an open-market transaction for about $51.2K on 2026-10-14.

Expected impact

Likely limited near-term impact, with any reaction confined to sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine insider sale (not a buy, not tied to a new corporate event) and the dollar value is relatively small versus typical CRSP trading/market cap scale.

Market effects

No clear sector read-through from a single small insider sale.

None.

None.

Counterpoint

The sale may be routine liquidity or tax-related, especially since the filing notes no pre-arranged 10b5-1 plan.

Key entities

  • CRISPR Therapeutics AG

    Company whose Form 4 insider sale is disclosed.

  • KASINGER JAMES R.

    General Counsel and Secretary who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.